Scleritis therapy

Ophthalmology

Volumn 119, Issue 1, 2012, Pages 51-58

  Sainz De La Maza, Maite ^a   Molina, Nicolas ^a   Gonzalez Gonzalez, Luis Alonso ^b,f   Doctor, Priyanka P ^c   Tauber, Joseph ^d   Foster, C Stephen ^b,e,f  

^a HOSPITAL CLÍNIC   (Spain)

^b MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^c Bay View Clinic   (India)

^d Tauber Eye Center   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f Massachusetts Eye Research and Surgery Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BIOLOGICAL RESPONSE MODIFIER; CELECOXIB; CERTOLIZUMAB PEGOL; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACLIZUMAB; DICLOFENAC; DIFLUNISAL; ETANERCEPT; IBUPROFEN; IMMUNOSUPPRESSIVE AGENT; INDOMETACIN; INFLIXIMAB; LEFLUNOMIDE; MELOXICAM; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; RAPAMYCIN; RITUXIMAB; STEROIDAL ANTIINFLAMMATORY DRUG; TACROLIMUS; TOCILIZUMAB; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; ELECTRONIC MEDICAL RECORD; EYE DISEASE; EYE INFLAMMATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NECROTIZING SCLERITIS; NODULAR SCLERITIS; NONINFECITIOUS ANTERIOR SCLERITIS; NONINFECTIOUS ANTERIOR SCLERITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCLERITIS; SYSTEMIC DISEASE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTERIOR EYE SEGMENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SCLERITIS; TREATMENT OUTCOME;

EID: 84855309332     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2011.07.043     Document Type: Article

References (25)

1. Sainz de la Maza M, Jabbur NS, Foster CS. Severity of scleritis and episcleritis. Ophthalmology 1994;101:389-96. (Pubitemid 24077041)
2. Tuft SJ, Watson PG. Progression of scleral disease. Ophthalmology 1991;98:467-71.
3. Sainz de la Maza M, Jabbur NS, Foster CS. An analysis of therapeutic decision for scleritis. Ophthalmology 1993;100: 1372-6. (Pubitemid 23274032)
4. Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology 2008;115:1416-21.
5. Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol 2010;149:423-32.
6. Thorne JE, Jabs DA, Qazi FA, et al. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 2005;112:1472-7. (Pubitemid 41074642)
7. Doctor P, Sultan A, Syed S, et al. Infliximab for the treatment of refractory scleritis. Br J Ophthalmol 2010;94:579-83.
8. Sen HN, Sangave A, Hammel K, et al. Infliximab for the treatment of active scleritis [report online]. Can J Ophthalmol 2009;44:e9-12. Available at: http://www.eyesite.ca/CJO/4403/i09-061.pdf. Accessed July 3, 2011.
9. Ahn SJ, Oh JY, Kim MK, Wee WR. Treating refractory scleritis with infliximab [letter]. Jpn J Ophthalmol 2009;53:286-7.
10. Restrepo JP, Molina MP. Successful treatment of severe nodular scleritis with adalimumab. Clin Rheumatol 2010;29:559-61.
11. Watson PG, Hazleman BL, Pavesio CE, Green WR. Treatment of Scleral and Associated Inflammatory Disease. In: The Sclera and Systemic Disorders. 2nd ed. Oxford, UK: Butterworth-Heinemann; 2004:298-9.
12. Iaccheri B, Androudi S, Bocci EB, et al. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocul Immunol Inflamm 2010;18:223-5.
13. Chauhan S, Kamal A, Thompson RN, et al. Rituximab for treatment of scleritis associated with rheumatoid arthritis [letter]. Br J Ophthalmol 2009;93:984-5.
14. Taylor SR, Salama AD, Joshi L, et al. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2009;60:1540-7.
15. Onal S, Kazokoglu H, Koc A, Yavuz S. Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener's granulomatosis. Ocul Immunol Inflamm 2008;16:230-2.
16. Cheung CM, Murray PI, Savage CO. Successful treatment of Wegener's granulomatosis associated scleritis with rituximab [letter]. Br J Ophthalmol 2005;89:1542. (Pubitemid 41527407)
17. Thorne JE, Jabs DA. Ocular manifestations of the rheumatic diseases. In: Tasman W, Jaeger EA, eds. Duane's Clinical Ophthalmology [book on CD-ROM]. vol. 5. Philadelphia, PA: Lippincott Williams & Wilkins; 2006. Available at: http://www.oculist.net/downaton502/prof/ebook/duanes/pages/v5/v5c026.html. Accessed July 3, 2011.
18. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92. (Pubitemid 24065492)
19. Watson PG. The diagnosis and management of scleritis. Ophthalmology 1980;87:716-20. (Pubitemid 10080282)
20. Jabs DA, Mudun A, Dunn JP, Marsh MJ. Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol 2000;130:469-76.
21. Akpek EK, Thorne JE, Qazi FA, et al. Evaluation of patients with scleritis for systemic disease. Ophthalmology 2004;111:501-6. (Pubitemid 38293106)
22. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
23. Sainz de la Maza M, Foster CS, Jabbur NS. Scleritis associated with rheumatoid arthritis and with other systemic immune-mediated diseases. Ophthalmology 1994:101:1281-6; discussion 1287-8.
24. Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study [report online]. BMJ 2009;339:b2480. Available at: http://www.bmj.com/content/339/bmj.b2480.full.pdf. Accessed July 3, 2011.
25. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized clinical trials. JAMA 2006;295:2275-85. (Pubitemid 43736578)